Pear Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Pear Therapeutics's estimated annual revenue is currently $35.4M per year.
- Pear Therapeutics received $64.0M in venture funding in January 2019.
- Pear Therapeutics's estimated revenue per employee is $157,891
- Pear Therapeutics's total funding is $409M.
Employee Data
- Pear Therapeutics has 224 Employees.
- Pear Therapeutics grew their employee count by 5% last year.
Pear Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.3M | 80 | 16% | N/A | N/A |
#2 | $2M | 18 | 0% | N/A | N/A |
#3 | $6.6M | 51 | -11% | $29.3M | N/A |
#4 | $4M | 33 | 3% | N/A | N/A |
#5 | $77M | 0 | N/A | $866M | N/A |
#6 | $0.5M | 6 | -14% | N/A | N/A |
#7 | $2.8M | 26 | 13% | N/A | N/A |
#8 | $174.6M | 810 | 19% | N/A | N/A |
#9 | $18.9M | 129 | 19% | $23.3M | N/A |
#10 | $2147M | 9958 | 3% | N/A | N/A |
What Is Pear Therapeutics?
At Pear, our mission is clear: we are pioneers in Prescription Digital Therapeutics, or PDTs. Our cross-functional team operates at the intersection of biotechnology and software technology. Pear discovers, develops, and delivers clinically-validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Every day, we push the boundaries of technology to transform medicine. Pear has a pipeline of products and product candidates across therapeutic areas, including mental health disorders, severe insomnia and multiple sclerosis. Our lead product, reSET®, treats Substance Use Disorder, and was the first PDT to receive marketing authorization from the FDA to treat disease. Pear's second product candidate, reSET-O for the treatment of Opioid Use Disorder, is currently under review by the FDA with Breakthrough Designation. For more information, visit us at www.peartherapeutics.com.
keywords:Biotechnology,Gaming,Healthcare,Human Resources Hr,Information Security,Medical Diagnostics,Mobile,Pharmaceuticals,Security
$409M
Total Funding
224
Number of Employees
$35.4M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pear Therapeutics News
Pear to host panel discussion with leaders who are paving the way to provide patients access to prescription digital therapeutics for the...
Boston-based Pear's program offers patients seeking treatment for substance use disorder (SUD) or opioid use disorder (OUD) access to a...
In its first year-end financial report after going public via reverse merger last December, Pear Therapeutics inched past nearly all of its predictions for...
What You Should Know: – Pear Therapeutics, the leader in developing and commercializing prescription digital therapeutics to treat serious disease, and Thimble Point Acquisition Corp (Nasdaq: THMA), a special purpose acquisition company (SPAC) whose management team is associated with the Pritzk ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $45M | 224 | N/A | N/A |
#2 | $60.3M | 226 | 15% | N/A |
#3 | $76M | 226 | -1% | N/A |
#4 | $62.4M | 226 | -1% | $21M |
#5 | $15M | 227 | 7% | N/A |
Pear Therapeutics Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2015-03-23 | $Undisclosed | Undisclosed | 5AM Ventures | Article |
| 2016-02-05 | $20.0M | Undisclosed | 5AM Ventures | Article |
| 2018-01-03 | $50.0M | B | Temasek | Article |
| 2019-01-07 | $64.0M | C | Temasek | Article |